Lumida
/TNGX
⌘K
Tango Therapeutics Inc

Tango Therapeutics Inc

TNGX
$23.78USD+1.75%+0.41 today

MARKET CAP

4.0B

P/E (TTM)

FWD P/E

DAY RANGE

$23 – $25

52W RANGE

$6
$34

AI Summary

Stalk
TrimMedium

TNGX is exhibiting Stage 3 distribution characteristics, with price below declining 9 and 20 EMAs and a recent bounce into the 20 EMA that has not been decisively rejected. The medium-term bias remains bearish, favoring sell-side engagement on rallies. Short-term conditions are neutral, suggesting deferred execution until resistance at the 20/9 EMA zone is confirmed. The long-term uptrend above the 200 DMA is intact but would be threatened by a breakdown below the 50 SMA.

  • 92% objective response rate in MTAP-deleted, RAS-mutant pancreatic cancer Phase 1/2 trial
  • $1 billion cash as of June 2026 extends funding into late-stage studies
  • Q2 net loss of $55.3 million (-$0.37/share) with $0 collaboration revenue
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$37.0M$24.9M$36.5M$42.1M$62.4M
YoY %-32.9%+46.9%+15.2%+48.3%
P / Sales18.3x25.8x25.8x8.0x16.5x
EV / Sales18.7x30.9x28.1x9.2x15.5x
Gross Profit, Adj.$37.0M$24.9M$36.5M$42.1M$62.4M
YoY %-32.9%+46.9%+15.2%+48.3%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit18.7x30.9x28.1x9.2x15.5x
EBITDA, Adj.$-57.3M$-109.5M$-111.8M$-143.1M$-109.0M
YoY %-91.1%-2.1%-28.0%+23.8%
Margin %-154.7%-440.3%-306.0%-340.1%-174.7%
EV / EBITDA-12.1x-7.0x-9.2x-2.7x-8.9x
EBIT$-58.2M$-111.1M$-114.2M$-145.6M$-111.3M
YoY %-90.9%-2.8%-27.5%+23.6%
Margin %-157.1%-446.8%-312.6%-346.1%-178.4%
EV / EBIT-11.9x-6.9x-9.0x-2.6x-8.7x
Net Income$-58.2M$-108.2M$-101.7M$-130.3M$-101.6M
YoY %-85.8%+5.9%-28.1%+22.0%
Net Margin-157.2%-435.1%-278.5%-309.7%-162.9%
EPS (GAAP)-$0.94-$1.23-$1.08-$1.19-$0.87
YoY %-30.9%+12.2%-10.2%+26.9%